accessibilityaccreditedactiveactivityaimalarmalign-bottomalign-center-horizontalalign-center-verticalalign-leftalign-rightalign-topanchorangelannoyedapplearchivearrow-downarrow-leftarrow-rightarrow-uparticleat-signawardbalanceballoonbandaidbarcodebellbicyclebinocularsblindboatbook-closedbookbookmarkbookmarkedbooksbottlebriefcasebrushbugbullhornbuscabinetcakecalendarcameracarcashcertificatechalkchart-barschart-linechart-piechatcheckmarkchevron-downchevron-leftchevron-rightchevron-upcircle-arrow-downcircle-arrow-leftcircle-arrow-rightcircle-arrow-upcircle-backwardcircle-checkmarkcircle-chevron-downcircle-chevron-leftcircle-chevron-rightcircle-chevron-upcircle-crosscircle-ejectcircle-exclamationcircle-facebookcircle-firstcircle-forwardcircle-googlepluscircle-gustcircle-lastcircle-linkedincircle-minuscircle-nextcircle-pausecircle-play-thincircle-playcircle-pluscircle-previouscircle-questioncircle-stopcircle-twittercircleclipboard-checkclipboardclockcloud-databasecloud-downloadcloud-fogcloud-gearcloud-lightningcloud-lockcloud-raincloud-snowcloud-synccloud-uploadcloudcocktail-glasscodecombinecomment-fillcommentcommentscompassconfusedconnectconstruction-coneconstructioncontactscoolcopycredit-cardcropcrosscrowncubedatabasedeletedesigndesktopdiamonddicedinnerdisconnectdocumentdownloaddrawerdreamdropletdumbbellearthediteggellipsisenter-downenter-leftenter-rightenter-upenterenvelopeevilexcludeexit-downexit-leftexit-rightexit-upexitexpandeye-droppereyefacebookfactoryfeatherfile-audiofile-codefile-imagefile-videofile-zipfilefilm-playfindfirefirst-aidflagflip-horizontalflip-verticalfloppy-diskfolderfootprintframefunnelgamepadgasgeargiftglassglassesgoogleplusgraduationgrin-evilgringroupgungusthamburgerhammerhappy-grinhappyheadsetheart-fillhearthistoryhomeiconsinboxintersectipadiphonekeykeyboardkeyholeknifelablamplaptopleafleave-downleave-leftleave-rightleave-uplibrarylifebuoylighterlightning-boltlinklinkedinlistlocationlocklotusmadmagicmagnetmalletmanmapmedalmeet-downmeet-leftmeet-rightmeet-upmic-mutemicminusmoonmousemovemusic-notemusicmustachemutenavigationneutralnewsoptionsoutletpaint-rollerpaintbrushpairpaper-planepaperclippaperspastepatchpawpenpencilphonephotopicturepinpine-treeplaneplayplaylistplug-cordpluspodiumpowerpresentationprinterprofilepulsepuzzlequestionquote-closequote-openradiorank1rank2rank3receptionrecycleredorefreshregisterreply-allreplyroad-signrocketrulersadscissorsscreensearchshareshieldshipshirtshockedshrinkshufflesignalsitemapskullsmartphonesmilespeed-fastspeed-mediumspeed-slowspell-checksquaresubtractsunsyncsyringetabtablettagtagstargetteacupterminalthumbs-downthumbs-uptickettilestimertoilet-papertonguetoolstrailertraintransmissiontrashtreetrophytrucktvtwitterumbrellaundounlinkunlockuploaduserusersvolume-highvolume-lowvolume-mediumvolumewarningwheelchairwifiwinkwomanwonderingwrenchzoom-inzoom-out

Share:

Invest in Sense Diagnostics

Medical technology to detect neurological disorders of the brain

  • $1,331,880Amount raised
  • $10,000Minimum
  • $9,000,000Pre-Money valuation

Purchased securities are not listed on any exchange. A secondary market for these securities does not currently exist and may never develop. You should not purchase these securities with the expectation that one eventually will.

Sense Diagnostics is accepting investments for an Offering under Regulation D through SI Securities, LLC ("SI Securities"). SI Securities is an affiliate of SeedInvest Technology, LLC, a registered broker-dealer, and member FINRA/SIPC. SI Securities will receive cash compensation equal to 7.50% of the value of the securities sold and equity compensation equal to 5.00% of the number of securities sold. The contents of the Highlights, Term Sheet sections have been prepared by SI Securities, LLC (“SI Securities”) and shall be deemed broker-dealer communications subject to FINRA Rule 2210 (the “Excluded Sections”). With the exception of the Excluded Sections noted above, this profile contains offering materials prepared solely by Sense Diagnostics without the assistance of SI Securities, and not subject to FINRA Rule 2210 (the “Issuer Profile”). The Issuer Profile may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.


Company Highlights

  • Received approval from the U.S. Food & Drug Administration (FDA) to begin pivotal human trial on initial 50 of 400 subjects
  • The Company holds an exclusive, global license to two published patents in the United States and Europe for the design and function of the product
  • Key investors include Cleveland Clinic Foundation (Global Cardiovascular Innovation Center), Accelerant Fund, Queen City Angels, and numerous physicians
  • Recipient of non-dilutive grant worth $1.5 million over the previous 5 years from the National Science Foundation and Ohio
  • Registered as an Industry Partner for NATO’s Committee of the Chiefs of Military Medical Services (COMEDS) 2020 in the Netherlands

Fundraise Highlights

  • Total Amount Raised: US $1,331,880
  • Total Round Size: US $2,369,996
  • Raise Description:  Series B
  • Minimum Investment:  US $10,000 per investor
  • Security Type:  Preferred Equity
  • Pre-Money valuation :  US $9,000,000

Sense Diagnostics is creating devices which detect, measure, and monitor stroke and traumatic brain injuries -both in hospital and in the field, reducing time to treatment. Time is brain, for every minute of delay millions of brain cells die.


Time is brain. The inability to effectively triage a stroke or traumatic brain injury patient in the field and to monitor their condition in the Neuro ICU can result in significant delays in receiving proper treatment. On average a patient sent to the wrong hospital can be delayed ~5 hours before being transferred to the right hospital for treatment, resulting in moderate to severe impairment or even death. In the hospital, patients sent to the Neuro ICU that are at risk of hemorrhage expansion or monitored using the same subjective methods used in the field, again result in delays in treatment. Over 60% percent of stroke patients suffer moderate to severe impairment or die. For every 1mL expansion of an intracranial hemorrhage, a patient faces a 7% greater risk of needing permanent assistance (i.e. nursing home) even after discharge.

Sense technology’s goal is to be able to determine if a patient is suffering a hemorrhage from a traumatic brain injury or is having a stroke by type (small or large vessel blockage or intracranial hemorrhage), giving emergency personnel the necessary triage information to deliver that patient to the nearest hospital that provides the required treatment their patient's condition requires. In the Neuro ICU, patients are at risk for hemorrhage expansion within 12-24 hours after onset. Our on-going monitoring capability will alert medical personnel if an expansion occurs so necessary treatment can begin. 

Our first inhuman trial for the in-hospital monitoring device has successfully completed with 100% concurrence to CT scans, no false positives, and no false negatives. We have secured funding from National Science Foundation for the completion of our field monitor device. We have been approved by the FDA to start out pivotal trial for in-hospital monitoring. Emory University is the lead hospital for the trial.

Pitch Deck

The Team

Founders and Officers

Geoff has held executive positions at both GE and Pfizer. He worked in numerous startups including the Jacobs Institute, specifically focused on bringing neuromuscular devices from ideas to reality.

Geoffrey Klass

CEO

Geoff has held executive positions at both GE and Pfizer. He worked in numerous startups including the Jacobs Institute, specifically focused on bringing neuromuscular devices from ideas to reality.

Daniel Kincaid

President/COO

Dan is a Serial Entrepreneur and a seasoned startup and health care executive. He previously founded and led a pharmacy benefits management company.

Daniel Kincaid

President/COO

Dan is a Serial Entrepreneur and a seasoned startup and health care executive. He previously founded and led a pharmacy benefits management company.

Opeal's field is in Emergency Medicine and Neurocritical Care. He is Associate Professor of Emergency Medicine and Neurosurgery at the University of Cincinnati. He is Co-Director of the UC Stroke Team.

Opeal Adeoye, MD

CMO

Opeal's field is in Emergency Medicine and Neurocritical Care. He is Associate Professor of Emergency Medicine and Neurosurgery at the University of Cincinnati. He is Co-Director of the UC Stroke Team.

George is a Ph.D of Physics and works at the Naval Research Labs specifically on radar development. He is a professor at the University of Cincinnati. Dr Shaw is also an Emergency Medicine Physician.

George Shaw, MD

CTO

George is a Ph.D of Physics and works at the Naval Research Labs specifically on radar development. He is a professor at the University of Cincinnati. Dr Shaw is also an Emergency Medicine Physician.

Matthew Flaherty, MD

Clinical Trial Leader

Matthew is a neurologist, specializing in stroke and vascular neurology at the University of Cincinnati Hospitals. He boasts in-depth clinical research experience.

Matthew Flaherty, MD

Clinical Trial Leader

Matthew is a neurologist, specializing in stroke and vascular neurology at the University of Cincinnati Hospitals. He boasts in-depth clinical research experience.

Joseph Korfhagen, PhD

VP, Product Development

Joseph Korfhagen, PhD

VP, Product Development

Frequently Asked Questions

Making an Investment in Sense Diagnostics
How does investing work?

When you complete your investment on SeedInvest, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by Sense Diagnostics. Once Sense Diagnostics accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to Sense Diagnostics in exchange for your securities. At that point, you will be a proud owner in Sense Diagnostics.


What is the difference between preferred equity and a convertible note?

Preferred equity is usually issued to outside investors and carries rights and conditions that are different from that of common stock. For example, preferred equity may include rights that prevent or minimize the effects of dilution or grants special privileges in situations when the company is sold.

A convertible note is a unique form of debt that converts into equity, usually in conjunction with a future financing round. The investor effectively loans money to a startup with the expectation that they will receive equity in the company in the future at a discounted price per share when the company raises its next round of financing.

To learn more about startup investment types check out “How to Choose a Startup Investment” in our academy.


What will I need to complete my investment?

To make an investment, you will need the following information readily available:

  1. Personal information such as your current address and phone number
  2. Employment and employer information
  3. Net worth and income information
  4. Social Security Number or passport
  5. ABA bank routing number and checking account number (typically found on a personal check or bank statement)

Because Sense Diagnostics is offering its securities under Rule 506(c) of Regulation D, your status as an Accredited Investor will also need to be verified and you will be asked to provide documentation supporting your income, net worth, revenue, or net assets or a letter from a qualified advisor such as a Registered Investment Advisor, Registered Broker Dealer, Lawyer, or CPA.


What if I change my mind about investing?

Until a closing occurs, you may cancel your investment at any time, for any reason. You will receive an email when the closing occurs and your securities have been issued. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To cancel your investment, please go to your portfolio page by clicking your profile icon in the top right corner.


After My Investment
How can I sell my securities in the future?

Currently there is no market or liquidity for these securities. Right now Sense Diagnostics does not plan to list these securities on a national exchange or another secondary market. At some point Sense Diagnostics may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when Sense Diagnostics either lists their securities on an exchange, is acquired, or goes bankrupt.


How do I keep track of this investment?

You can return to SeedInvest at any time to view your portfolio of investments and obtain a summary statement.


Other General Questions
What is this page about?

This is Sense Diagnostics's fundraising profile page, where you can find information that may be helpful for you to make an investment decision in their company. The information on this page includes the company overview, team bios, and the risks and disclosures related to this investment opportunity.


What are the risks of this investment?

This investment is highly speculative and should not be made by anyone who cannot afford to risk the entire investment amount. In addition to these risks, you should carefully consider the specific information and risks disclosed in Sense Diagnostics’s profile.